Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-18 of 18 for your search:
Cancer Type/Condition:
Mesothelioma
Stage/Subtype:
recurrent malignant mesothelioma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
2005_010
, MK0683-014, NCT00128102
2.
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MCC-14896
, USFIRB#105715, AVF3483s, NCT00604461
3.
AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-14203B
, NCI-7103, 7103, NCT00309946
4.
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
AVF3442S
, NCT00295503
5.
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
TL139204
, NCT00685204
6.
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
Protocol Amdt 6 dated 092508
, AAAB9658, NCT00859495
7.
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
AAAD4868
, NCT00996385
8.
Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0205
, NCI-5270, 5270, NCT00041158
9.
FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-05-C-0010
, 5987, NCI-5987, NCT00098644
10.
Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06C.549
, NCT00437372
11.
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2006-1068
, NCT00491855
12.
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181084
, NCT00528619
13.
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NCI-08-C-0026
, 08-C-0026, P07188, CAT-5001-1001, NCT00575770, 8210
14.
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
AAAC3255
, NCT00629343
15.
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UMN-2007LS086
, UMN-2007LS086, 0712M22703, BAYER-UMN-2007LS086, NCT00703638
16.
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-091
, NCT00571298
17.
Dasatinib in Resectable Malignant Pleural Mesothelioma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0935
, NCT00652574
18.
Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HSC-2007-0109
, NCT00585819
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
